Top 29 CAR-T startups

Oct 23, 2024 | By Jason Kwon

These startups develop CAR T-cell therapy - a form of immunotherapy that uses specially altered T cells — a part of the immune system — to fight cancer.
1
Country: USA | Funding: $112M
AvenCell Therapeutics develops next generation immunotherapies for hard-to-treat cancers.
2
Country: USA | Funding: $87.6M
Inceptor Bio develops cell therapy solutions to cure difficult-to-treat cancers.
3
Fate Therapeutics
Country: USA | Funding: $1.3B
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
4
Autolus
Country: UK | Funding: $1.1B
Autolus utilises advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
5
Allogene Therapeutics
Country: USA | Funding: $1B
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
6
Poseida Therapeutics
Country: USA | Funding: $460.5M
Poseida Therapeutics utilizes best-in-class genome engineering capabilities to develop targeted lifesaving therapeutics.
7
Cellectis
Country: France | Funding: $388.2M
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.
8
Humanigen
Country: USA | Funding: $369.5M
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy.
9
Capstan Therapeutics
Country: USA | Funding: $340M
Capstan Therapeutics is advancing cell engineering to develop CAR-T therapeutics for a broad range of diseases.
10
Sotio Biotech
Country: Czech Republic | Funding: $316.9M
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit.
Editor: Jason Kwon
Jason Kwon is a senior editor for MedicalStartups. He has previously covered the pharmaceutical and medical research industries for FDAnews and worked as a head of marketing for medical startup Sonic Therapeutics. Before that, he co-founded a startup consulting business for emerging entrepreneurial hubs in Asia. Jason graduated from St. Bonaventure University’s journalism school. In his free time, Jason enjoys yoga, watching movie trailers, traveling to places where he can't get cell service. You can contact Jason at jaskwon(at)medicalstartups(dot)com